CO4940400A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
CO4940400A1
CO4940400A1 CO98031614A CO98031614A CO4940400A1 CO 4940400 A1 CO4940400 A1 CO 4940400A1 CO 98031614 A CO98031614 A CO 98031614A CO 98031614 A CO98031614 A CO 98031614A CO 4940400 A1 CO4940400 A1 CO 4940400A1
Authority
CO
Colombia
Prior art keywords
pharmaceutically acceptable
compound
composition
pharmaceutical compositions
optionally
Prior art date
Application number
CO98031614A
Other languages
English (en)
Inventor
Patel Jai
Ross Hamish
Roger Granett Jaffrey
Robin Price
Paul Niger Wray
Original Assignee
Smithkline Beecham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham filed Critical Smithkline Beecham
Publication of CO4940400A1 publication Critical patent/CO4940400A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica que comprende 5-[4-[2-(N-metil-N-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona [aquí en lo sucesivo ´Compuesto (I)´], caracterizada porque la composición comprende de 2 a 12 mg de Compuesto ( I ) en una forma farmacéuticamente aceptable y opcionalmente un vehículo farmacéuticamente aceptable para el mismo. Procedimiento para preparar un compuesto (I) en forma farmacéuticamente aceptable junto a un vehículo farmacéuticamente aceptable, el cual comprende la preparación de una primera composición con base en un compuesto (I) y un vehículo farmacéuticamente aceptables, y mezclar dicha primera composición con un segundo vehículo farmacéuticamente aceptable para suministrar la composición de compuesto (I) y opcionalmente formular la composición resultante en forma administrable.
CO98031614A 1997-06-05 1998-06-04 Composiciones farmaceuticas CO4940400A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
CO4940400A1 true CO4940400A1 (es) 2000-07-24

Family

ID=26311662

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98031614A CO4940400A1 (es) 1997-06-05 1998-06-04 Composiciones farmaceuticas

Country Status (29)

Country Link
EP (1) EP0998284A1 (es)
JP (1) JP2001521553A (es)
KR (1) KR20010013410A (es)
CN (3) CN1112926C (es)
AP (1) AP1214A (es)
AR (2) AR015120A1 (es)
AU (1) AU8215098A (es)
BG (1) BG104048A (es)
BR (1) BR9810405A (es)
CA (2) CA2292629C (es)
CO (1) CO4940400A1 (es)
DZ (1) DZ2510A1 (es)
EA (1) EA002384B1 (es)
GB (1) GB9711683D0 (es)
HU (1) HUP0004070A3 (es)
ID (1) ID24264A (es)
IL (1) IL133074A0 (es)
MX (1) MXPA99011322A (es)
NO (2) NO995938L (es)
NZ (2) NZ523725A (es)
OA (1) OA11306A (es)
PE (1) PE78899A1 (es)
PL (1) PL337201A1 (es)
SK (1) SK164899A3 (es)
TR (2) TR199902963T2 (es)
TW (1) TW570797B (es)
UY (1) UY25032A1 (es)
WO (1) WO1998055122A1 (es)
ZA (2) ZA9811572B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515168A (en) * 1999-04-23 2004-02-27 Smithkline Beecham Plc Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
AU765498B2 (en) 1999-04-23 2003-09-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2270007A1 (en) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
JPH09512249A (ja) * 1994-02-10 1997-12-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 腎臓疾患を治療するためのインスリンセンシタイザーの使用
KR19990036290A (ko) * 1995-08-10 1999-05-25 로즈 암스트롱 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
NZ513922A (en) 2001-09-28
PL337201A1 (en) 2000-08-14
IL133074A0 (en) 2001-03-19
EA199901116A1 (ru) 2000-06-26
CN1112926C (zh) 2003-07-02
CA2292629A1 (en) 1998-12-10
AU8215098A (en) 1998-12-21
TR200002790T2 (tr) 2001-11-21
CN1526391A (zh) 2004-09-08
SK164899A3 (en) 2000-11-07
KR20010013410A (ko) 2001-02-26
PE78899A1 (es) 1999-10-22
AP1214A (en) 2003-10-08
ID24264A (id) 2000-07-13
CA2333352A1 (en) 1998-12-10
CN1430959A (zh) 2003-07-23
HUP0004070A3 (en) 2002-03-28
WO1998055122A1 (en) 1998-12-10
NO995938L (no) 2000-02-02
CN1259050A (zh) 2000-07-05
EP0998284A1 (en) 2000-05-10
ZA984826B (en) 1999-08-03
DZ2510A1 (fr) 2003-01-25
TR199902963T2 (xx) 2000-02-21
ZA9811572B (en) 1999-07-22
OA11306A (en) 2003-10-22
AR015120A1 (es) 2001-04-18
HUP0004070A2 (hu) 2002-02-28
UY25032A1 (es) 1998-11-26
GB9711683D0 (en) 1997-08-06
NO995938D0 (no) 1999-12-03
BG104048A (bg) 2000-07-31
NO20040738L (no) 2000-02-02
EA002384B1 (ru) 2002-04-25
TW570797B (en) 2004-01-11
AP9901696A0 (en) 1999-12-31
MXPA99011322A (es) 2004-12-02
CA2292629C (en) 2004-01-06
NZ523725A (en) 2004-09-24
BR9810405A (pt) 2000-08-29
JP2001521553A (ja) 2001-11-06
AR008198A1 (es) 1999-12-29

Similar Documents

Publication Publication Date Title
CO4940400A1 (es) Composiciones farmaceuticas
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
CA2271196A1 (en) Pharmaceutical compositions of hiv protease inhibitors with improved oral bioavailability
CA2338358A1 (en) Compounds and compositions for delivering active agents
CA2339765A1 (en) Compounds and compositions for delivering active agents
EP1093819A3 (en) Compounds and compositions for delivering active agents
CA2360220A1 (en) Oxadiazole compounds and compositions for delivering active agents
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
WO2002026737A8 (en) Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AR038417A1 (es) Forma de dosificacion oral, procedimiento para prepararla y uso de una base debil farmaceuticamente aceptable o una sal o solvato farmaceuticamente aceptable de la misma para preparar dicha forma de dosificacion oral
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
WO2000069425A3 (de) Endoparasitizide synergistische kombination enthaltend cyclischen depsipeptiden und piperazinen
AU2002343052A1 (en) Rosiglitazone edisylates and their use as antidiabetics
USD444182S1 (en) Set of heximoes
IT1298442B1 (it) Composizioni orali a basso dosaggio di proteine citotossiche
GB0021784D0 (en) Novel pharmaceutical
NZ510672A (en) Composition comprising 5-[4-[2-(N-Methyl-N-2-Pyridyl)Amino)-Ethoxy]Benzyl]Thiazolidine-2,4-Dione
GB2402335B (en) Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form
CO5150180A1 (es) Nueva composicion y uso liberacion modificada
MX9601756A (es) Composicion liquida estable que contiene urato-oxidasa, y composicion liofilizada para su preparacion.
MY139034A (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
ECSP982520A (es) Composicion
ECSP992852A (es) Compuestos organicos
ECSP003434A (es) Nuevos compuestos